Molecular biologists in the School of Medicine at The University of Texas Health Science Center San Antonio have found a novel way to fine-tune the activity of cells' protein-disposing machinery, with potentially cancer-fighting effects.
This machinery, the proteasome, is deregulated in cancer. Agents called protease inhibitors are viewed as potential anti-cancer therapies, but they indiscriminately curb proteasome activity, which also includes protein recycling. Such strategy is effective to kill cells in aggressive blood cancers but leads to drug resistance and excessive toxicity in solid tumors.
The new strategy may change that. By basically outsmarting the cell's machinery, compounds called allosteric regulators are able to fine-tune the proteasome actions instead of block them. "The result is that cell lines from solid tumors, which are resistant to existing therapy, are sensitive to these agents," said Pawel Osmulski, Ph.D., assistant professor of molecular medicine at the Health Science Center. He and Maria Gaczynska, Ph.D., associate professor of molecular medicine, co-authored a report in Molecular Pharmacology that provides a basis for this approach.
Deregulation of the proteasome's actions is noted in cancer or during aging and contributes to intracellular pathologies. "It is easy to envision that precise adjusting of the proteasome activities with therapeutic molecules would be highly beneficial in many human conditions," Dr. Osmulski said.
Inhibition and activation
"Allosteric regulators are better than proteasome-affecting agents used in clinics because they do not induce classical drug resistance," Dr. Gaczynska said. "They bind to sites on the proteasome molecule used by natural regulatory proteins. They are more specific and are not restricted to proteasome inhibition but can activate the proteasome under certain conditions."
The new strategy was serendipitously found during experiments with rapamycin, a drug that in a highly publicized study by the UT Health Science Center's Barshop Institute for Longevity and Aging Studies was found to extend life span in mice.
The Molecular Pharmacology report and follow-up studies describe the unexpected and highly desired effects that rapamycin and similar compounds elicit on the proteasome. Based on these studies, it would be possible to design a new line of proteasome regulators with anti-cancer properties, Drs. Osmulski and Gaczynska said. This work is in progress in their laboratory. Drs. Osmulski and Gaczynska are affiliated with the Barshop Institute and with the Cancer Therapy & Research Center at The University of Texas Health Science Center San Antonio.The work was supported by the Mike Hogg Fund (to Maria Gaczynska), the William and Ella Owens Medical Research Foundation (to Maria Gaczynska), and the Institute for Integration of Medicine and Science Pilot Grant (to Pawel Osmulski). http://molpharm.aspetjournals.org/content/early/2013/04/25/
On Web and social media
For current news from the UT Health Science Center San Antonio, please visit our news release website, like us on Facebook or follow us on Twitter.
About the UT Health Science Center San Antonio
The University of Texas Health Science Center at San Antonio, one of the country's leading health sciences universities, ranks in the top 3 percent of all institutions worldwide receiving National Institutes of Health funding. The university's schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced approximately 28,000 graduates. The $736 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways "We make lives better®," visit http://www.uthscsa.edu
Will Sansom | EurekAlert!
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences